# The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)

> **NCT00152178** · PHASE3 · COMPLETED · sponsor: **Taiho Pharmaceutical Co., Ltd.** · enrollment: 680 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** UFT (uracil, tegafur) and tamoxifen
- **DRUG:** CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen

## Key facts

- **NCT ID:** NCT00152178
- **Lead sponsor:** Taiho Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-07
- **Primary completion:** 2008-04
- **Final completion:** 2008-08
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2011-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00152178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00152178, "The Comparative Trial of UFT + TAM With CMF + TAM in Adjuvant Therapy for Breast Cancer (CUBC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00152178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*